title: Exceptional Response on Addition of Everolimus to Taxane in Urothelial Carcinoma Bearing an NF2 Mutation.
authors: Foundation Medicine, Cambridge, MA, USA.
authors: Siraj M
authors: SM
authors: Ali
authors: Foundation Medicine, Cambridge, MA, USA.
authors: Vincent A
authors: VA
authors: Miller
authors: Foundation Medicine, Cambridge, MA, USA.
authors: Jeffrey S
authors: JS
authors: Ross
authors: Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: spal@coh.org.
authors: Sumanta K
authors: SK
authors: Pal
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001952:Bridged-Ring Compounds / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D000068338:Everolimus / Q000627:therapeutic use*; D020022:Genetic Predisposition to Disease; D006801:Humans; D009154:Mutation; D016518:Neurofibromatosis 2 / Q000235:genetics*; D043823:Taxoids / Q000627:therapeutic use*; D016896:Treatment Outcome; D001743:Urinary Bladder / Q000187:drug effects / Q000473:pathology*; D014571:Urologic Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D043823:Taxoids; C080625:taxane; D000068338:Everolimus